Plate Nº 22 · recorded November 16, 2026
Health & Medicine ResearchReported finding
97% in youth hormone survey call treatment the right decision
A survey of 376 transgender and gender-diverse young people found 97% regarded hormone therapy as the right decision, while access faces restrictions in 28 states.
By Priya Raman3 min read648 words
In brief
- 97% of 376 surveyed participants said hormone therapy was the right decision.
- 10 participants, about 3%, reported regret; 7 of the 10 called the experience harmful.
- Nearly 92% began hormones at 17 or younger; 30% took estrogen and 70% took testosterone.
- The average time since starting hormones was five years; survey submissions covered 2023-2025.
- KFF reported 28 states with laws or policies limiting gender-affirming care as of November 2026.

By Priya Raman
Nearly 97% of 376 transgender and gender-diverse young people said gender-affirming hormone therapy (treatment that aligns physical changes with gender) was the right decision for them. Researchers reported the finding November 9 in JAMA Pediatrics. They described it as the largest survey of its kind to date.
At the U.S. Supreme Court in 2025, demonstrators rallied in support of gender-affirming health care for transgender youth. The rally took place against a background of state restrictions and reduced access to treatment.
What did the survey find?
The U.S. survey included 376 participants who had attended a clinic for transgender and gender-diverse youth, a group close to 400. The study measured satisfaction with hormone therapy, regret, age at initiation and time since starting.
Nearly 92 percent began hormones at 17 or younger. Thirty percent took estrogen, 70 percent took testosterone, and the average time since starting was five years.
Ten participants, about 3 percent of the group, said they regretted the decision. Seven of those 10 described the experience as harmful. These reports show why the nearly 97 percent satisfaction rate does not speak for every participant.
The researchers wrote: “the results provide further support for the existing standards of care [and] do not support efforts to categorically restrict or ban access.” In this context, standards of care (clinical guidelines for treatment) formed the focus of their conclusion.
How did researchers follow participants?
For transgender health care, clinical guidelines call for a young person interested in medical treatment to attend an assessment visit with a mental health professional, with a parent or guardian joining the visit. That first visit supplied the reference point for later follow-up.
Participants completed a questionnaire once a year. They could submit it from one month before to six months after the anniversary of the initial assessment, creating a series of annual check-ins rather than a one-time snapshot. Researchers analyzed survey submissions from 2023 through 2025.
What can the results show?
The report places the satisfaction findings within a growing body of evidence on gender-affirming hormone therapy. The authors describe the treatment as improving alignment between appearance and gender, increasing satisfaction with life and reducing depression and anxiety. The five-year average shows that many respondents were assessing long-term experience, although the survey does not by itself establish each benefit directly.
Because participants were former patients of one clinic and supplied their own reports, the results cannot by themselves show that hormone therapy caused changes in well-being or predict every young person’s experience.
The survey reports no separate outcomes for estrogen and testosterone users, and its findings address hormone therapy rather than puberty blockers, another treatment that can fall within gender-affirming care. A large sample does not remove those design limits.
Why does access remain contested?
With concerns about youth well-being helping to drive restrictions, state bans have curtailed access to gender-affirming care. KFF, a health policy organization, reported that 28 states had laws or policies limiting such care as of November 2026. More than half of transgender young people ages 13 to 17 lived in states with those restrictions.
The survey does not measure the effects of those laws. It reports the experiences of former clinic patients rather than the effects of restrictions on every young person seeking care.
The American Academy of Pediatrics and the Endocrine Society support gender-affirming health care for young people and provide evidence-backed treatment guidelines. Those positions contrast with the laws and policies tracked by KFF, although the survey does not examine how restrictions affect treatment choices or outcomes.
The study offers a clear measure of experience, not a final answer for every patient: most respondents call hormone therapy the right choice, a small minority report regret and harm, and access continues to narrow in much of the country.
via sciencenews.org (Source)
More from Priya Raman
Show full bio
Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.
425 articles
Nearby plates
- Teen Health Visits Linked to Adult Chronic Pelvic Pain Risk
- 78% of Psychology's Masculinity Scales Measure Only the Negative
- Loneliness and Desire for Thinness Explain Much of the Teen Girls' Depression Gap
- Steroid Users Face Triple the Risk of Long-Term Erectile Dysfunction
- Medical Records Barely Track Menopause, Study of 240,000 Women Finds